Robert J. Hopkin, MD, on Assessing ST-920 for Fabry Disease
The associate professor of clinical pediatrics at Cincinnati Children's Hospital Medical Center discussed Sangamo Therapeutics’ gene therapy, ST-920, and the phase 2 STAAR clinical trial.
Robert J. Hopkin, MD, on the Unmet Needs in Fabry Disease Treatment
The associate professor of clinical pediatrics at Cincinnati Children's Hospital Medical Center discussed the limitations of the current standard of care for Fabry disease.
